Dyne's DYNE-101 Shows One-Year Functional Improvement In DM1 Study

September 29, 2026 — 11:12 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Tuesday, Dyne Therapeutics (DYN) reported additional one-year data from the Phase 1/2 ACHIEVE trial showing that zeleciment basivarsen (DYNE-101) improved multiple functional measures in patients with myotonic dystrophy type 1 (DM1).

The data showed functional improvement versus baseline, placebo, and a matched natural history cohort, while continued benefits were observed at six months in video hand opening time (vHOT), an emerging indicator of clinical benefit in DM1.

Dyne said topline data from the registrational expansion cohort of the ACHIEVE study remain on track for the first quarter of 2027 and could support a potential U.S. Accelerated Approval submission in the third quarter of 2027.

Dyne's closed Tuesday's trading at $16.21, down 0.80%. In afterhours trading, the stock is at $16.75, up 3.33%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Dyne's DYNE-101 Shows One-Year Functional Improvement In DM1 Study

Tags

Latest Articles